Furthermore, promising target antigens, such as CD30 in Hodgkin ́s lymphoma and colon cancer [33,39], or CD5 on T-cell lymphoma [40], are co-expressed by healthy T cells creating the risk of durable damage to endogenous healthy T-cells upon targeting by conventional CAR T-cells. The gene discussed is CD5; the disease is Hodgkins lymphoma.